Abstract
Background:
This study investigates the efficacy and the feasibility of a chemotherapy regimen with topotecan plus vincristine and doxorubicin (TVD) given on an individually tailored basis to patients with refractory/recurrent rhabdomyosarcoma (RMS).
Patients and methods:
Nine patients received TVD therapy at relapse, and six were assessable for response.
Results:
All the six patients experienced objective response after two cycles of chemotherapy: one minor response, four partial response, and one complete response.
Conclusions:
The value of our study is severely limited by the small number of cases, the single-institutional setting and the individually tailored treatment, but we nonetheless confirmed the feasibility and tolerability of topotecan-based chemotherapy in RMS.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Antibiotics, Antineoplastic / administration & dosage
-
Antibiotics, Antineoplastic / adverse effects
-
Antineoplastic Agents, Phytogenic / administration & dosage
-
Antineoplastic Agents, Phytogenic / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Child
-
Child, Preschool
-
Doxorubicin / administration & dosage*
-
Doxorubicin / adverse effects
-
Drug Administration Schedule
-
Female
-
Humans
-
Infusions, Intravenous
-
Male
-
Neoplasm Recurrence, Local
-
Rhabdomyosarcoma / drug therapy*
-
Rhabdomyosarcoma / pathology
-
Topotecan / administration & dosage*
-
Topotecan / adverse effects
-
Treatment Outcome
-
Vincristine / administration & dosage*
-
Vincristine / adverse effects
Substances
-
Antibiotics, Antineoplastic
-
Antineoplastic Agents, Phytogenic
-
Vincristine
-
Topotecan
-
Doxorubicin